BridgeBio Pharma, Inc. (BBIO) saw its shares plummet 5.01% during intraday trading on Wednesday.
The decline came as analysts issued mixed target price revisions for the biopharmaceutical company. While Leerink Partners and Morgan Stanley raised their price targets to $98, and Truist Securities increased its target to $95, Oppenheimer cut its target price to $81 from $83.
This divergence in analyst sentiment, with one notable downward revision amid several upward adjustments, may have prompted investor caution and contributed to the stock's sharp decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.